See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Nintendo
Donald Trump
Natural Disasters
Baseball
Republican Party
Social Media
US Politics
European Union
Democratic Party
Taxes
Senate
Published • loading... • Updated

Bavarian Nordic’s Jynneos highlights unmet need for mpox prevention in HIV patients

Summary by Clinical Trials Arena
A recent study has shown that one dose of Bavarian Nordic’s Jynneos vaccine was overall 58% effective at preventing mpox infection.The post Bavarian Nordic’s Jynneos highlights unmet need for mpox prevention in HIV patients appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Clinical Trials ArenaClinical Trials Arena

Bavarian Nordic’s Jynneos highlights unmet need for mpox prevention in HIV patients

A recent study has shown that one dose of Bavarian Nordic’s Jynneos vaccine was overall 58% effective at preventing mpox infection.The post Bavarian Nordic’s Jynneos highlights unmet need for mpox prevention in HIV patients appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Tuesday, April 1, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Mpox

Mpox

Vaccines

Vaccines

HIV

HIV

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal